CCI Approved Merger of 9 Companies With Sequent Scientific Limited

On January 21, 2025, the Competition Commission of India gave its approval for the proposed merger of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn, and SV Labs with Sequent Scientific Limited.

Sequent Scientific Limited (SSL) is a publicly listed company with global operations in the animal healthcare industry. It offers a broad range of Active Pharmaceutical Ingredients (APIs), finished dosage formulations (FDFs), and analytical services to meet the needs of the animal health sector. Sequent Research Limited (SRL), a wholly owned subsidiary of SSL, operates as a Contract Research Organization, providing analytical services and a variety of testing for the global pharmaceutical industry.

Viyash Life Sciences Private Limited (Viyash) is a pharmaceutical company, and through its subsidiaries, it is mainly involved in the development, manufacture, and sale of APIs and intermediates for human healthcare in India. Viyash also produces FDFs for human healthcare. Its wholly owned subsidiaries include Symed Labs Limited (Symed), Appcure Labs Private Limited (Appcure), Vindhya Pharma (India) Private Limited (Vindhya Pharma), and Vandana Life Sciences Private Limited (Vandana), while SV Labs Private Limited (SV Labs) is a wholly owned step-down subsidiary of Viyash through Vindhya Pharma.

Geninn Life Sciences Private Limited (Geninn) is a holding company without direct operations but owns Vindhya Organics Private Limited (Vindhya Organics), which focuses on the development, manufacture, and marketing of APIs for human healthcare.

The Proposed Combination entails a series of interconnected steps aimed at merging SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn, and SV Labs into SSL, which will be the ultimate surviving entity.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.